Myriad Genetics (MYGN) Long-Term Deferred Tax (2010 - 2016)

Myriad Genetics (MYGN) has reported Long-Term Deferred Tax for 7 consecutive years, with $12.7 million the latest figure, recorded in Q2 2016.

• In Q2 2016, Long-Term Deferred Tax changed N/A year-over-year to $12.7 million; the TTM figure through Jun 2016 stood at $12.7 million (changed N/A YoY), while the FY2016 annual figure was $12.7 million, changed N/A from the prior year.
• Long-Term Deferred Tax retreated to $12.7 million in Q2 2016 per MYGN's latest filing, from $13.5 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $30.6 million in Q2 2012 and bottomed at $407000.0 in Q1 2015.
• Historically, Long-Term Deferred Tax has averaged $21.3 million across 5 years, with a median of $27.0 million in 2012.
• Annual changes were most pronounced in 2013 — Long-Term Deferred Tax increased 21.93% — and 2014, when it tumbled 88.82%.
• Myriad Genetics' Long-Term Deferred Tax stood at $24.6 million in 2012, then rose by 21.93% to $30.0 million in 2013, then slumped by 89.33% to $3.2 million in 2014, then surged by 321.88% to $13.5 million in 2015, then dropped by 5.93% to $12.7 million in 2016.
• Business Quant data shows MYGN's Long-Term Deferred Tax at $12.7 million in Q2 2016, $13.5 million in Q4 2015, and $407000.0 in Q1 2015.